STAAR Surgical's stock leapt in morning trading, climbing roughly 14.5% after the company reported first-quarter 2026 results that outpaced Wall Street's estimates by a wide margin. The company recorded earnings per share of $0.10, which was double the consensus analyst forecast, and reported revenue of $93.5 million, a year-over-year increase of 119.6%.
On the profitability line, STAAR swung to net income of $5.2 million, or $0.10 per diluted share, compared with a net loss of $54.2 million, or $1.10 per diluted share, in the year-earlier quarter. Gross margin expanded to 73.6% from 65.8%, reflecting both top-line improvement and margin leverage.
Company management pointed to China as the principal driver of the quarter's gains. In January 2026 STAAR officially launched the next-generation EVO+ implantable collamer lens (ICL) in that market. The EVO+ ICL was described as having a larger optical zone and improved night vision performance, and the company has positioned the product at a premium price point to target higher-end demand in China.
Investors were further reassured by operational details indicating reduced geopolitical and tariff risk. STAAR noted that its Swiss manufacturing facility is slated to supply 100% of the EVO ICL and EVO+ ICL lenses shipped to China in 2026 without import tariffs. Management also said distributor inventories that contributed to an overhang in 2025 have been brought within targeted ranges, with in-market sales and procedures showing improvement.
The U.S. regulatory environment also contributed to the companys addressable market. The FDA approved an age extension for the EVO ICL to include patients aged 21 to 60, which management quantified as adding roughly 8 million potential patients to the eligible population.
Following the results, sell-side analysts revised their views. Wedbush upgraded STAAR to an Outperform rating and raised its price target from $26 to $40, citing confidence that the company is at or approaching an inflection point for a full rebound in China. Piper Sandler increased its price target to $33 from $16 but kept a Neutral rating.
Beyond the fundamental beat and fresh analyst price targets, the share surge was amplified by short covering. Heavy short interest that accumulated over the prior year was forced to unwind on the surprise earnings strength, which passively magnified the single-day advance. The broader U.S. equity market provided a modestly constructive backdrop, with the S&P 500 up 0.33%, the Dow Jones rising 0.76%, and the NASDAQ adding 0.22%.
The confluence of a historic earnings beat, a decisive upgrade with a substantially higher price target, and visible progress in correcting a prior channel inventory overhang combined to create a powerful near-term catalyst. Shares reached a new 52-week high of $35.87 during the trading session.
Market context and takeaway
STAAR's quarter showcased simultaneous improvement across revenue growth, margin expansion, and a return to profitability. Management emphasized China as the primary growth engine following the EVO+ launch, while operational moves - including planned Swiss production shipments to China without tariffs and normalized distributor inventory levels - helped address investor concerns tied to channel dynamics and trade barriers. The FDA age extension materially enlarges the potential U.S. patient population.
Analyst actions and forced short covering reinforced the market reaction, turning the strong report into a dramatic intraday move and sending the stock to a year high.